Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jardiance in type 2 diabetes mellitus
NCT03437330Phase 4Withdrawn
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2021
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Skeletal muscle H2O2 concentration at 12 weeks. Planned start Oct 2021; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03437330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437330.